The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 10 January 2006, www.theannals.com, DOI 10.1345/aph.1G170.
 The Annals of Pharmacotherapy: Vol. 40, No. 2, pp. 286-289. DOI 10.1345/aph.1G170
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maier, S. K
Right arrow Articles by Hammond, J. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maier, S. K
Right arrow Articles by Hammond, J. M

DRUG INFORMATION ROUNDS

Role of Lenalidomide in the Treatment of Multiple Myeloma and Myelodysplastic Syndrome

Sara K Maier, PharmD

Oncology Specialty Resident, Department of Pharmacy, Duke University Medical Center, Durham, NC

Julia M Hammond, PharmD

Oncology Clinical Coordinator, Department of Pharmacy, Duke University Medical Center

Reprints: Dr. Maier, Department of Pharmacy, Duke University Medical Center, DUMC Box 3089, Durham, NC 27710-3089, fax 919/681-2741, sara.maier{at}duke.edu

OBJECTIVE: To evaluate lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome (MDS).

DATA SOURCES: Clinical literature was accessed through MEDLINE (1966-August 2005), Science Citation Index (1980-August 2005), and Proceedings of the American Society of Hematology (2000-2004).

DATA SYNTHESIS: New analogs of thalidomide have been synthesized that are more potent and less toxic. Lenalidomide (CC-5013) is currently in Phase III trials for the treatment of multiple myeloma and MDS. Phase II trials demonstrated lenalidomide's efficacy in patients refractory to thalidomide. The full potential of this agent has yet to be proven, but preliminary data seem promising.

CONCLUSIONS: Lenalidomide is a potent immunomodulating drug that offers different mechanisms of action and therapeutic potential for the treatment of multiple myeloma, MDS, and other malignancies.

Key Words: lenalidomide, multiple myeloma, myelodysplastic syndrome, thalidomide

Published Online, January 10, 2006. www.theannals.com, DOI 10.1345/aph.1G170




homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.